Published in Lab Business Week, September 26th, 2004
Based on their high level of confidence in the company's leadership and the promise of its lead product, a second-generation transdermal contraceptive, The Hillman Company, TL Ventures and PA Early Stage Partners, participated to the full extent of their rights.
"Agile Therapeutics has a strong opportunity to bring an exciting product into a rapidly growing segment of the women's healthcare market. We at TL are pleased to continue our support for Agile on its path to commercial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.